HDL therapy for the acute treatment of atherosclerosis
RS Newton, BR Krause - Atherosclerosis Supplements, 2002 - Elsevier
Although pharmacologic intervention to treat atherosclerosis originally focused on lowering
LDL-cholesterol levels as a therapeutic target, a number of intervention trials have also …
LDL-cholesterol levels as a therapeutic target, a number of intervention trials have also …
HDL in the 21st century: a multifunctional roadmap for future HDL research
A Rohatgi, M Westerterp, A Von Eckardstein… - Circulation, 2021 - Am Heart Assoc
Low high-density lipoprotein cholesterol (HDL-C) characterizes an atherogenic dyslipidemia
that reflects adverse lifestyle choices, impaired metabolism, and increased cardiovascular …
that reflects adverse lifestyle choices, impaired metabolism, and increased cardiovascular …
Treatment options for low high-density lipoproteins
A Hafiane, S Kellett, J Genest - Current Opinion in Endocrinology …, 2014 - journals.lww.com
Targeting HDL-C has, to date, not led to changes in the cardiovascular outcomes. Novel
therapeutic advances target the HDL function. In keeping with the recent 2013 American …
therapeutic advances target the HDL function. In keeping with the recent 2013 American …
Reconstituted HDL for the acute treatment of acute coronary syndrome
BR Krause, AT Remaley - Current opinion in lipidology, 2013 - journals.lww.com
Summary rHDL is a promising new potential therapy for ACS patients, but much work
remains to be done, and there are many unresolved questions. Progress in developing …
remains to be done, and there are many unresolved questions. Progress in developing …
High density lipoprotein-should we raise it?
U Landmesser - Current vascular pharmacology, 2012 - ingentaconnect.com
Low high-density lipoprotein (HDL) cholesterol levels are associated with an increased risk
of coronary artery disease and myocardial infarction. Experimental studies have identified …
of coronary artery disease and myocardial infarction. Experimental studies have identified …
HDL therapy for the treatment of cardiovascular diseases
C Parolini, M Marchesi, G Chiesa - Current vascular …, 2009 - ingentaconnect.com
High-density lipoprotein (HDL) therapy is an emerging area of therapeutic development in
the cardiovascular field, aimed at supplementing and improving the vascular benefit exerted …
the cardiovascular field, aimed at supplementing and improving the vascular benefit exerted …
Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality
High-density lipoprotein (HDL) particles are highly complex polymolecular aggregates
capable of performing a remarkable range of atheroprotective functions. Considerable …
capable of performing a remarkable range of atheroprotective functions. Considerable …
ApoA-I infusion therapies following acute coronary syndrome: Past, present, and future
Abstract Purpose of Review The elevated adverse cardiovascular event rate among patients
with low high-density lipoprotein cholesterol (HDL-C) formed the basis for the hypothesis …
with low high-density lipoprotein cholesterol (HDL-C) formed the basis for the hypothesis …
Targeting high density lipoproteins in the prevention of cardiovascular disease?
DB Larach, EM deGoma, DJ Rader - Current cardiology reports, 2012 - Springer
Recent studies involving HDL-raising therapeutics have greatly changed our understanding
of this field. Despite effectively raising HDL-C levels, niacin remains of uncertain clinical …
of this field. Despite effectively raising HDL-C levels, niacin remains of uncertain clinical …
HDL-C: does it matter? An update on novel HDL-directed pharmaco-therapeutic strategies
R Gadi, A Amanullah, VM Figueredo - International journal of cardiology, 2013 - Elsevier
It has long been recognized that elevated levels of low-density lipoprotein cholesterol (LDL-
C) increase the risk of cardiovascular disease (CHD) and that pharmacologic therapy to …
C) increase the risk of cardiovascular disease (CHD) and that pharmacologic therapy to …